On July 11, 2025, analyst Stephen Baxter from Wells Fargo issued a downgrade for Oscar Health (OSCR, Financial). The rating was lowered from 'Equal-Weight' to 'Underweight'. This change reflects a more cautious stance on the stock's performance expectations.
Additionally, Wells Fargo has adjusted its price target for Oscar Health (OSCR, Financial), reducing it from $16.00 to $10.00. This adjustment represents a significant decrease of 37.50%. The revised price target aligns with the current market challenges and the company's performance outlook as perceived by the analyst.
Investors in Oscar Health (OSCR, Financial) should note these updates in the analyst ratings and price target, as they may have implications for the stock's future performance and investor sentiment.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 9 analysts, the average target price for Oscar Health Inc (OSCR, Financial) is $14.74 with a high estimate of $21.00 and a low estimate of $8.00. The average target implies an downside of 0.78% from the current price of $14.86. More detailed estimate data can be found on the Oscar Health Inc (OSCR) Forecast page.
Based on the consensus recommendation from 11 brokerage firms, Oscar Health Inc's (OSCR, Financial) average brokerage recommendation is currently 2.9, indicating "Hold" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
Based on GuruFocus estimates, the estimated GF Value for Oscar Health Inc (OSCR, Financial) in one year is $14.67, suggesting a downside of 1.25% from the current price of $14.855. GF Value is GuruFocus' estimate of the fair value that the stock should be traded at. It is calculated based on the historical multiples the stock has traded at previously, as well as past business growth and the future estimates of the business' performance. More detailed data can be found on the Oscar Health Inc (OSCR) Summary page.
